Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 851 to 900 of 2052 results for work

  1. Multimorbidity: clinical assessment and management (NG56)

    This guideline covers optimising care for adults with multimorbidity (multiple long-term conditions) by reducing treatment burden (polypharmacy and multiple appointments) and unplanned care. It aims to improve quality of life by promoting shared decisions based on what is important to each person in terms of treatments, health priorities, lifestyle and goals. The guideline sets out which people are most likely to benefit from an approach to care that takes account of multimorbidity, how they can be identified and what the care involves.

  2. Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing (NG117)

    This guideline sets out an antimicrobial prescribing strategy for managing and preventing acute exacerbations of bronchiectasis (non-cystic fibrosis). It aims to optimise antibiotic use and reduce antibiotic resistance.

  3. AdenoPlus point-of-care test for diagnosing adenoviral conjunctivitis (MIB46)

    NICE has developed a medtech innovation briefing (MIB) on the AdenoPlus point-of-care test for diagnosing adenoviral conjunctivitis

  4. Omalizumab for previously treated chronic spontaneous urticaria (TA339)

    Evidence-based recommendations on omalizumab (Xolair) for treating severe chronic spontaneous urticaria in people of 12 and over.

  5. Delgocitinib for treating moderate to severe chronic hand eczema (TA1107)

    Evidence-based recommendations on delgocitinib (Anzupgo) for treating moderate to severe chronic hand eczema in adults when topical corticosteroids have not worked or are not suitable.

  6. Pressure redistributing devices: Dopressure redistributing devices reduce the development of pressure ulcers for those who are at risk of developing a pressure ulcer?

    include different types of mattresses, overlays, cushions and seating. They may work by reducing or redistributing pressure, friction or...

  7. Pain management: chronic pancreatitis:- Is the long-term use of opioids more clinically effective and cost effective than non-opioid analgesia (including non-pharmacological analgesia) in people with chronic pain due to chronic pancreatitis?

    also multifactorial, making it difficult to have a standard regimen that can work for everyone. Some people also develop psychosocial...

  8. Lifestyle interventions (diet and exercise):- Are specialist lifestyle interventions (diet and exercise) effective, compared with no specialist lifestyle interventions, for women with endometriosis?

    activities of daily living, including relationships and sexuality, ability to work, fertility, fitness and mental health.Supporting...

  9. What community-based interventions are effective and cost effective in improving dietary habits affecting the oral health of children and adults, and in particular those at high risk of poor oral health?

    out, and the effect on independent living such as admissions to care homes, work related effects including sickness absence. Source...

  10. What community-based interventions are effective and cost effective in improving oral health and reducing oral health inequalities among groups of adults at high risk of poor oral health?

    out, and the effect on independent living such as admissions to care homes, work related effects including sickness absence. Source...

  11. What community-based interventions are effective and cost effective in improving oral health and reducing oral health inequalities among groups of children at high risk of poor oral health?

    out, and the effect on independent living such as admissions to care homes, work related effects including sickness absence. Source...

  12. Pain management programmes:- Are pain management programmes a clinically and cost-effective intervention for women with endometriosis?

    chronic, and can adversely affect the woman's quality of life, ability to work, and can affect partners and their families.Pain...

  13. What is the relative effectiveness and cost effectiveness of the different components of multi-component, community-based oral health improvement programmes?

    out, and the effect on independent living such as admissions to care homes, work related effects including sickness absence. Source...

  14. Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373)

    Evidence-based recommendations on abatacept (Orencia), adalimumab (Humira), etanercept (Enbrel) and tocilizumab (RoActemra) for treating juvenile idiopathic arthritis in children, young people and adults.

  15. Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant (TA640)

    Evidence-based recommendations on treosulfan (Trecondi) with fludarabine for conditioning treatment before allogeneic haematopoietic stem cell transplant for malignant diseases in people for whom a reduced intensity regimen would be suitable.

  16. NICE HealthTech programme manual (PMG48)

    This guide describes the methods and processes that NICE follows when producing HealthTech guidance. For interventional procedures, this guide covers NICE processes. Methods for interventional procedures guidance are in the NICE's interventional procedures programme manual. The NICE HealthTech programme combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme

  17. What community-based interventions are effective and cost effective at improving the uptake of, and reducing inequalities in the use of, dental services by groups of adults and children at high risk of poor oral health?

    out, and the effect on independent living such as admissions to care homes, work related effects including sickness absence. Source...

  18. Roxadustat for treating symptomatic anaemia in chronic kidney disease (TA807)

    Evidence-based recommendations on roxadustat (Evrenzo) for treating symptomatic anaemia associated with chronic kidney disease in adults.

  19. Constipation in children and young people (QS62)

    This quality standard covers the diagnosis and management of constipation of unknown cause in babies, children and young people (from birth to 18 years). It describes high-quality care in priority areas for improvement.

  20. Idiopathic pulmonary fibrosis in adults (QS79)

    This quality standard covers managing idiopathic pulmonary fibrosis (gradual scarring of the lungs) in adults. It includes diagnosis by a multidisciplinary team, managing symptoms and palliative care. It describes high-quality care in priority areas for improvement.

  21. Intravenous fluid therapy in children and young people in hospital (QS131)

    This quality standard covers managing intravenous (IV) fluids safely and effectively for babies, children and young people (from birth to 16) in hospital. It describes high-quality care in priority areas for improvement.

  22. Irritable bowel syndrome in adults (QS114)

    This quality standard covers diagnosing and managing irritable bowel syndrome in adults. It describes high-quality care in priority areas for improvement.

  23. Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes (NG5)

    This guideline covers safe and effective use of medicines in health and social care for people taking 1 or more medicines. It aims to ensure that medicines provide the greatest possible benefit to people by encouraging medicines reconciliation, medication review, and the use of patient decision aids.

  24. Antenatal and postnatal mental health: clinical management and service guidance (CG192)

    This guideline covers recognising, assessing and treating mental health problems in women who are planning to have a baby, are pregnant, or have had a baby or been pregnant in the past year. It covers depression, anxiety disorders, eating disorders, drug- and alcohol-use disorders and severe mental illness (such as psychosis, bipolar disorder and schizophrenia). It promotes early detection and good management of mental health problems to improve women’s quality of life during pregnancy and in the year after giving birth.

  25. Schizophrenia: omega-3 fatty acid medicines (ESUOM19)

    Summary of the evidence on omega-3 fatty acid medicines for treating schizophrenia to inform local NHS planning and decision-making

  26. Guide to the technology appraisal and highly specialised technologies appeal process (pre June 2023) (PMG18)

    This document concerns the appeal process for the technology appraisal and highly specialised technologies programmes and provides an overview for organisations wishing to lodge an appeal

  27. Cabozantinib for treating medullary thyroid cancer (TA516)

    Evidence-based recommendations on cabozantinib (Cometriq) for treating medullary thyroid cancer in adults.

  28. Ixekizumab for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA718)

    Evidence-based recommendations on ixekizumab (Taltz) for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis in adults.

  29. Charging procedure

    Charging procedure for NICE technology appraisal and highly specialised technologies evaluations

  30. Treating an eating disorder in people with a comorbidity:- What is the impact of comorbidities on treatment outcomes for eating disorders, and whatapproaches are effective in managing these comorbidities?

    obsessive-compulsive disorder). However, there is little evidence on which treatments work best for people with an eating disorder and a...

  31. Major trauma: assessment and initial management (NG39)

    This guideline covers the rapid identification and early management of major trauma in pre-hospital and hospital settings, including ambulance services, emergency departments, major trauma centres and trauma units. It aims to reduce deaths and disabilities in people with serious injuries by improving the quality of their immediate care. It does not cover care for people with burns.

  32. The Juxta CURES adjustable compression system for treating venous leg ulcers (MIB25)

    NICE has developed a medtech innovation briefing (MIB) on the Juxta CURES adjustable compression system for treating venous leg ulcers

  33. Key question: responsive

    This resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.

  34. Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over (TA1044)

    Evidence-based recommendations on exagamglogene autotemcel (Casgevy) for treating severe sickle cell disease in people 12 years and over.

  35. Extended access to GP services:- Is extended access to GP services, for example during early mornings, evenings and weekends, more clinically and cost effective than standard access?

    extending opening hours of practices for the full spectrum of GPs' clinical work. [See the evidence review on GP extended hours.] Source...

  36. Gastroelectrical stimulation for gastroparesis (HTG341)

    Evidence-based recommendations on gastroelectrical stimulation for gastroparesis. This involves using a stimulating device to send electrical impulses to the stomach muscles to help them work normally.

  37. Antimicrobial stewardship (QS121)

    This quality standard covers the effective use of antimicrobial medicines (including antibiotics) to reduce the risk of antimicrobial resistance, which is when antimicrobial medicines lose their effectiveness. It covers all settings and all types of antimicrobials for treating bacterial, fungal, viral and parasitic infections. It describes high-quality care in priority areas for improvement.

  38. Next-generation sequencing panel for solid tumour cancers in children (MIB133)

    NICE has developed a medtech innovation briefing (MIB) on the next-generation sequencing panel for solid tumour cancers in children .

  39. Optilume for anterior urethral strictures (MIB241)

    NICE has developed a medtech innovation briefing (MIB) on Optilume for anterior urethral strictures .

  40. Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over (TA1093)

    Evidence-based recommendations on idebenone (Raxone) for treating visual impairment in Leber’s hereditary optic neuropathy in people 12 years and over.

  41. Cerebral palsy in under 25s: assessment and management (NG62)

    This guideline covers diagnosing, assessing and managing cerebral palsy in children and young people from birth up to their 25th birthday. It aims to make sure they get the care and treatment they need for the developmental and clinical comorbidities associated with cerebral palsy, so that they can be as active and independent as possible.

  42. Bipolar disorder: assessment and management (CG185)

    This guideline covers recognising, assessing and treating bipolar disorder (formerly known as manic depression) in children, young people and adults. The recommendations apply to bipolar I, bipolar II, mixed affective and rapid cycling disorders. It aims to improve access to treatment and quality of life in people with bipolar disorder.

  43. Effectiveness and cost effectiveness of drug misuse prevention interventions for groups vulnerable to drug misuse:- What is the effectiveness and cost effectiveness of drug misuse prevention interventions for groups vulnerable to drug misuse in the UK?

    drug misuse prevention interventions for people involved in commercial sex work or who are being sexually exploited, people not in...

  44. NICE announces Professor Jonathan Benger as new Chief Executive

    NICE Chairman, Sharmila Nebhrajani, today announced Professor Jonathan Benger CBE as incoming chief executive, with effect from Friday 19 December 2025 taking over from Dr Samantha Roberts.

  45. Faecal microbiota transplant for recurrent Clostridioides difficile infection (HTG638)

    Evidence-based recommendations on faecal microbiota transplant for recurrent Clostridioides difficile infection.

  46. Dupilumab for treating severe asthma with type 2 inflammation (TA751)

    Evidence-based recommendations on dupilumab (Dupixent) for treating severe asthma with type 2 inflammation that is inadequately controlled in people 12 years and over.

  47. Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C (TA365)

    Evidence-based recommendations on ombitasvir–paritaprevir–ritonavir (also known as Viekirax) with or without dasabuvir (also known as Exviera) for adults with some types (called genotypes) of chronic hepatitis C.

  48. Benralizumab for treating severe eosinophilic asthma (TA565)

    Evidence-based recommendations on benralizumab (Fasenra) for treating severe eosinophilic asthma in adults.

  49. Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years (TA213)

    Evidence-based recommendations on aripiprazole for treating schizophrenia in young people aged 15 to 17.

  50. Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease (TA607)

    Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events in adults with coronary or peripheral artery disease.